Thoratec Stock Gain Driven By Debut Of HeartMate II For Heart Failure
This article was originally published in The Gray Sheet
Executive Summary
Thoratec's recent launch of its HeartMate II continuous-flow ventricular assist device for advanced heart failure is driving sales growth that helped push the firm's stock up 51% in the third quarter to $26.25
You may also be interested in...
GE Gains Sleep Apnea, Anesthesia Products In $860 Mil. Vital Signs Purchase
GE Healthcare's $860 million acquisition of Vital Signs Inc. provides an entry into the rapidly growing sleep apnea market and complementary offerings for its anesthesia and broader respiratory care businesses
With Approval Of HeartMate II, Thoratec Aims To Double U.S. Implant Centers
Thoratec expects to double the number of U.S. centers implanting the HeartMate II continuous flowventricular assist device from 40 to 80 by the end of 2008
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.